Rarity receives prestigious SweLife grant together with SciLifeLabs, Karolinska Institutet, and Uppsala University Hospital

Rarity has been awarded a grant from Swelife and Medtech4Health – Collaboration project for better health, fall 2021. The project is a partner project with SciLifeLabs, Karolinska Institutet and Uppsala University Hospital. 

The aim of the project is to implement SuperRCA for precision diagnostics & relapse detection for Acute Myeloid Leukemia and Myelodysplastic syndrome – ultimately improving treatment outcome, reducing patient burden & cost. 

SuperRCA assays for mutation detection in liquid biopsies have been developed based on long standing research and prior collaborations withing oncology with a focus on hematology and Leukemia. The SuperRCA technology offers extreme sensitivity that enables clinicians to detect and track even the lowest levels of mutations and potential relapse during and after treatment. 

The project starts in April and will span over two years. It includes a large retrospective analysis of patient samples for the purpose of assessing the lower threshold for mutation relapse and possibilities for earlier detection, as well as the clinical usefulness of blood samples instead of costly and burdensome bone marrow samples for longitudinal patient monitoring.  

“We are really excited about this funding and the ability to run the project with such great partners. The project team includes superstar clinicians from Karolinska and Uppsala University Hospital, as well as laboratory experts from SciLifeLabs, with Rarity as the technology provider of SuperRCA assays for mutation detection. This is not only an important project for the involved parties, but also for the scientific and patient community as a whole.” – Linus Bosaeus, CEO Rarity Bioscience

About Swelife

Swelife – For a competitive life science ecosystem in Sweden 

Swelife is a strategic innovation program, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the program partners. We support collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health. 

About Medtech4health  

Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia and business, we contribute to increasing value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the innovation authority Vinnova and by the program partners. 

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »